MYELODYSPLASTIC SYNDROME; MDS
specificComment: may be designated as having features of a named human MDS; Morphologic dysgranulopoiesis, dyserythropoiesis, and/or dysplastic megakaryocytes (with or without increased immature forms/blasts)
46
Centers
24
Active Trials
—
Cancer Funding
Top Centers for MYELODYSPLASTIC SYNDROME; MDS(46)
Ranked by research excellence score (trials · grants · publications). Methodology →
| # | Center | Score |
|---|---|---|
| 1 | Memorial Sloan Kettering Cancer CenterNew York, NY NCI Comprehensive High-Volume Research Center | 73.1 |
| 2 | Moffitt Cancer CenterTampa, FL NCI Comprehensive High-Volume Research Center | 70.7 |
| 3 | University of Illinois Cancer CenterChicago, IL High-Volume Research Center | 70.7 |
| 4 | Boston University Cancer CenterBoston, MA High-Volume Research Center | 70.7 |
| 5 | High-Volume Research Center | 70.7 |
| 6 | Dana-Farber Cancer InstituteBoston, MA NCI Comprehensive Active Research Program | 62.3 |
| 7 | Fred Hutch Cancer CenterSeattle, WA NCI Comprehensive Active Research Program | 62.3 |
| 8 | NCI Comprehensive Active Research Program | 62.3 |
| 9 | Duke Cancer InstituteDurham, NC NCI Comprehensive Active Research Program | 62.3 |
| 10 | City of Hope Comprehensive Cancer CenterDuarte, CA NCI Comprehensive Active Research Program | 62.3 |
| 11 | NCI Comprehensive Active Research Program | 62.3 |
| 12 | Roswell Park Comprehensive Cancer CenterBuffalo, NY NCI Comprehensive Active Research Program | 62.3 |
| 13 | University of Virginia Cancer CenterCharlottesville, VA NCI Comprehensive Active Research Program | 62.3 |
| 14 | NCI Clinical Active Research Program | 62.3 |
| 15 | Cancer Center at IllinoisUrbana, IL Active Research Program | 62.3 |
| 16 | University of Cincinnati Cancer CenterCincinnati, OH Active Research Program | 62.3 |
| 17 | BC CancerVancouver, BC Active Research Program | 62.3 |
| 18 | Princess Margaret Cancer CentreToronto, ON Active Research Program | 62.3 |
| 19 | NCI Comprehensive | 42.3 |
| 20 | Abramson Cancer Center of the University of PennsylvaniaPhiladelphia, PA NCI Comprehensive | 42.3 |
| 21 | Stanford Cancer InstitutePalo Alto, CA NCI Comprehensive | 42.3 |
| 22 | UNC Lineberger Comprehensive Cancer CenterChapel Hill, NC NCI Comprehensive | 42.3 |
| 23 | UPMC Hillman Cancer CenterPittsburgh, PA NCI Comprehensive | 42.3 |
| 24 | Mayo Clinic Comprehensive Cancer CenterRochester, MN NCI Comprehensive | 42.3 |
| 25 | UC San Diego Moores Cancer CenterLa Jolla, CA NCI Comprehensive | 42.3 |
| 26 | NCI Comprehensive | 42.3 |
| 27 | NCI Comprehensive | 42.3 |
| 28 | Winship Cancer InstituteAtlanta, GA NCI Comprehensive | 42.3 |
| 29 | The Ohio State University Comprehensive Cancer Center - James Cancer Hospital & Solove Research InstituteColumbus, OH NCI Comprehensive | 42.3 |
| 30 | Masonic Cancer CenterMinneapolis, MN NCI Comprehensive | 42.3 |
| 31 | University of Colorado Cancer CenterAurora, CO NCI Comprehensive | 42.3 |
| 32 | Huntsman Cancer Institute at the University of UtahSalt Lake City, UT NCI Comprehensive | 42.3 |
| 33 | Hollings Cancer CenterCharleston, SC NCI Clinical | 42.3 |
| 34 | The University of Arizona Cancer CenterTucson, AZ NCI Comprehensive | 42.3 |
| 35 | Medical College of Wisconsin Cancer CenterMilwaukee, WI | 42.3 |
| 36 | Cedars-Sinai CancerLos Angeles, CA | 42.3 |
| 37 | Cleveland Clinic Cancer CenterCleveland, OH | 42.3 |
| 38 | NCI Basic_laboratory | 42.3 |
| 39 | The University of Kansas Cancer CenterKansas City, KS NCI Comprehensive | 42.3 |
| 40 | Rutgers Cancer InstituteNew Brunswick, NJ NCI Comprehensive | 42.3 |
| 41 | Karmanos Cancer InstituteDetroit, MI NCI Comprehensive | 42.3 |
| 42 | Penn State Cancer InstituteHershey, PA | 42.3 |
| 43 | Mayo Clinic Comprehensive Cancer Center, FloridaJacksonville, FL | 42.3 |
| 44 | Mayo Clinic Comprehensive Cancer Center, ArizonaScottsdale, AZ | 42.3 |
| 45 | Cardinal Bernardin Cancer CenterMaywood, IL | 42.3 |
| 46 | Louisiana Cancer Research CenterNew Orleans, LA | 42.3 |
Research tier badges reflect trial volume, NIH grant funding, and publication impact — not clinical outcomes or patient satisfaction. Learn about our methodology →